Marie-Berthe Maes

Marie-Berthe Maes

Auto-generated profile, based on publicly available information

Marie-Berthe Maes

Department of Clinical Biology, Antwerp University Hospital, Antwerp, Belgium

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
SBSévérine de Bruijn
Sévérine de Bruijn
MMMarie‐Berthe Maes
Marie‐Berthe Maes
LWLaure De Waele
Laure De Waele
KVKaren Vanhoorelbeke
Karen Vanhoorelbeke
AGAlain Gadisseur
Alain Gadisseur

18 September 2014 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
PDF file
TGT. Geens
T. Geens
FVF. Vertessen
F. Vertessen
RMR. Malfait
R. Malfait
KDK. Deiteren
K. Deiteren
MMM.B. Maes
M.B. Maes

19 October 2022 in Acta Clinica Belgica
Verified
Journal Article
Closed access
MBMichiel Beyens
Michiel Beyens
JEJessy Elst
Jessy Elst
MPMarie-Line van der Poorten
Marie-Line van der Poorten
AGAthina Van Gasse
Athina Van Gasse
ATAlessandro Toscano
Alessandro Toscano
VSVito Sabato
Vito Sabato
Mastocytosis is a complex heterogenous multisystem disorder that is characterized by pathologic activation or accumulation of neoplastic mast cells (MCs) in one or more organs. This clonal MC expansion is often associated with a somatic gain-of-function mutation (D816V in most of the cases) in the KIT gene, encoding for the MC surface receptor KIT (CD117), a stem cell growth factor receptor. Based on clinical and biochemical criteria, the World Health Organization (WHO) divided mastocytosis into different subclasses. The exact prevalence of mastocytosis remains elusive, but it is estimated that the disease affects approximately 1 in 10,000 persons. The clinical presentation of mastocytosis varies significantly, ranging from asymptomatic patients to a life-threatening disease with multiple organ involvement, potentially leading to cytopenia, malabsorption, hepatosplenomegaly, lymphadenopathy, ascites or osteolytic bone lesions with pathological fractures. Patients with mastocytosis may experience symptoms related to release of MC mediators, such as flushing or diarrhea or even more severe symptoms such as anaphylaxis. Recently, a new genetic trait, hereditary alpha tryptasemia (HaT), was described which involves a copy number variation in the TPSAB1-gene. Its role as standalone multisystem syndrome is heavily debated. There is emerging evidence suggesting there might be a link between HaT and due to the increased prevalence of HaT in patients with SM. The aim of this review is to provide a practical roadmap for diagnosis and management of mastocytosis and its associated entities, since there are still many misconceptions about these topics. Abbreviations: AdvSM: Advanced systemic mastocytosis; ASM: Aggressive systemic mastocytosis; aST: acute serum tryptase; BM: Bone marrow; BMM: Bone marrow mastocytosis; bST: baseline serum tryptase; CM: Cutaneous mastocytosis; DCM: Diffuse cutaneous mastocytosis; HVA: Hymenoptera venom allergy; HaT: Hereditary alpha tryptasemia; ISM: Indolent systemic mastocytosis; MC: Mast cell; MCA: Mast cell activation; MCAS: Mast cell activation syndrome; MCL: Mast cell leukemia; MIS: Mastocytosis in the skin; MMAS: Monoclonal mast cell activation syndrome; MPCM: Maculopapular cutaneous mastocytosis; SM: Systemic mastocytosis; SM-AHN: Systemic mastocytosis with associated hematological neoplasm; SSM: Smouldering systemic mastocytosis; VIT: Venom immunotherapy.

7 September 2026 in Acta Clinica Belgica
Verified
Journal Article
Closed access
EIElias Iturrospe
Elias Iturrospe
EBEva De Backer
Eva De Backer
MMMarie-Berthe Maes
Marie-Berthe Maes
KDKathleen Deiteren
Kathleen Deiteren
RFReinoud Flies
Reinoud Flies
CHCatharina van der Heijden
Catharina van der Heijden
We report the case of a patient with a de novo pathogenic germline variant causing GATA2 deficiency. GATA2 deficiency is a rare autosomal dominant inborn error of immunity caused by heterozygous lo...